0.48
0.00%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Zhong Ji Longevity Science Group
Its shares trade on HKEX under the ticker 767.HK. It has been listed since 20 November 1995. In the fiscal year to 31 December 2024, it reported a net loss of HK$34.7m. At that date it held total assets of HK$525.6m and shareholders' equity of HK$373.4m.
Zhong Ji Longevity Science Group Ltd is a HK-based company operating in Financial Services industry. Zhong Ji Longevity Science Group Ltd, formerly Asia Pacific Silk Road Investment Co Ltd, is an investment holding company principally engaged in the longevity science and money lending business. The firm mainly operates its business through five segments. The Longevity Science segment is engaged in longevity science research, longevity medical testing, longevity biological products, longevity management services and member division. The Money Lending segment is engaged in the money lending business and the provision of credits. The Securities and Other Investment segment is mainly engaged in the holding of equity investments and investment in short to long-term financial assets. The Property Investment segment is mainly engaged in the investment in properties for rental income and for potential capital appreciation. The Financial and Investment Advisory segment is mainly engaged in the provision of financial and investment consulting services.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Financials
- Industry
- Financial Services
- Listed since
- 20 Nov 1995
- Employees
- 33
Leadership
Pay as last reported
- Mr. Li YanExecutive Chairman of the Board, since 2020HK$621,000
- Mr. Yifan YanChief Executive Officer, Executive Director, since 2022
- Mr. Ning ChenChief Investment Officer, Chairman of the China Region
- Mr. Hon Siang ChinFinancial Controller
- Ms. Qiong Cao XieExecutive Director, since 2020HK$619,000
- Mr. Xiaoshuang LiExecutive Director, since 2021HK$206,000
- Mr. Yuk Hong YeungCompany Secretary
- Dr. Yiwu HeNon-Executive Director
- Mr. Changsheng LyuNon-Executive Director
- Prof. Cibo HuangNon-Executive Independent Director
- Mr. Jiang HuangNon-Executive Independent Director
- Mr. See Barry LeeNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company operates in Financial Services sector with a diversified business model across five segments.
- Company has been publicly traded since 1995 with a long history in the market.
- Company has a small employee base of 33, indicating operational efficiency.
Weaknesses
- Company's city location is unknown, creating uncertainty about its operational base.
- Company's business model includes money lending, which may carry higher financial risks.
- Company's historical name change from Asia Pacific Silk Road Investment Co Ltd suggests possible rebranding challenges.
Opportunities
- Growth potential in longevity science research and medical testing segments.
- Expansion in property investment for rental income and capital appreciation.
- Potential to leverage financial advisory services for additional revenue streams.
Threats
- Money lending business may face regulatory scrutiny and market volatility.
- Unknown city location may hinder investor confidence and market perception.
- Company's small employee count may limit scalability and operational capacity.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.